By Amy Sitnick
Diversity has certainly taken center stage in the clinical trial industry, with the FDA issuing guidance on the matter in November 2020: Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices and Trial Designs Guidance for Industry. Here at Greenphire, we’ve observed many organizations looking to make a difference in this arena, both before and increasingly after the FDA guidance.
To help guide organizations move beyond the problems that exist and discuss approaches and solutions, the DIA hosted their first ever meeting dedicated exclusively to Diversity, Equity and Inclusion in the Drug Development Lifecycle.
In this article, I’d like to share some of the key learnings from the event, so that you may brainstorm with your colleagues and connections, building further connection and action plans.